LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea

Contributed by: Business Wire

Logo

Tags

Research

Mental Health

Medical Devices

FDA

Clinical Trials

Cardiology

Biotechnology

Pharmaceutical

Health

Science

Sleep Apnea

More Like This

LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea

LivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual Meeting

LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea

LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea

LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance